Dostarlimab vs Serplulimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Dostarlimab

Marketed by GlaxoSmithKline and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT04655976 · Phase 2/3 · active, not recruiting

Patients were randomly assigned to three arms (758 enrolled) with docetaxel as the active comparator, but the study was open label, with no masking. The primary endpoint, overall survival, was not significantly improved by dostarlimab plus docetaxel (HR 0.96, 95% CI 0.77 to 1.20, p=0.37) or by the triplet with cobolimab (HR 0.85, 95% CI 0.68 to 1.06, p=0.08), so the primary comparisons were not met.

Next expected readout: January 2027 · NCT06879717 (registry estimate)

Reported efficacy

Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks); Overall Survival (OS) (Arm B Versus Arm C) (Up to approximately 234 weeks): Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 Months (95% CI 10.6 to 14.2) vs Docetaxel (Arm C) 11.3 Months (95% CI 9.5 to 13.9) (missed)

Result source: NCT04655976

Serplulimab

Marketed by Shanghai Henlius Biotech and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Weak signal

NCT05807893 · Phase 2/3 · completed

The study treated 40 participants in a non-randomized, open-label, single-arm design without a comparator group. Its primary endpoint was intracranial progression-free survival. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: June 2027 · NCT07253142 (registry estimate)

Reported efficacy

tumor assessment (Baseline until disease progression or death, whichever occurs first (up to approximately 24months)): At the final analysis, serplulimab plus chemotherapy significantly improved median OS compared to placebo plus chemotherapy (HR 0.73, 95% CI 0.58-0.93; p=0.010); at the second interim analysis, the PFS benefit was maintained in the serplulimab-chemotherapy group (HR 0.53, 95% CI 0.42-0.67). (met)

Result source: NCT04033354

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointDostarlimabSerplulimab
PFS, median4.4 vs 4.1vs Docetaxeln 305NCT04655976
2 other results
—Not posted · NCT05807893
OS, median11.9 vs 11.3vs Docetaxeln 305NCT04655976
3 other results
—Not posted · NCT05807893
ORR18.7% vs 14.5%vs Docetaxeln 305NCT04655976
2 other results
—Not posted · NCT05807893
Duration of response, median8.3 vs 8.8vs Docetaxeln 57NCT04655976
2 other results
—Not posted · NCT05807893

PFS, median

Dostarlimab
4.4 vs 4.1vs Docetaxeln 305NCT04655976
2 other results
Serplulimab
—Not posted · NCT05807893

OS, median

Dostarlimab
11.9 vs 11.3vs Docetaxeln 305NCT04655976
3 other results
Serplulimab
—Not posted · NCT05807893

ORR

Dostarlimab
18.7% vs 14.5%vs Docetaxeln 305NCT04655976
2 other results
Serplulimab
—Not posted · NCT05807893

Duration of response, median

Dostarlimab
8.3 vs 8.8vs Docetaxeln 57NCT04655976
2 other results
Serplulimab
—Not posted · NCT05807893
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Dostarlimab: 3 of 4 rows · Serplulimab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDostarlimabSerplulimab
Dropout rate
25.6%Cobolimab + Dostarlimab + Docetaxea
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 3 more results
21.6%Dostarlimab + Docetaxel (Arm B)
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
—Stage 2 (Cohort 1A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
—Stage 2 (Cohort 2A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
—
Discontinued due to AEs
—Cobolimab + Dostarlimab + Docetaxea
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 3 more results
—Dostarlimab + Docetaxel (Arm B)
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
—Stage 2 (Cohort 1A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
—Stage 2 (Cohort 2A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
—
Serious AEs
33.8%Cobolimab + Dostarlimab + Docetaxea
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 3 more results
42.7%Dostarlimab + Docetaxel (Arm B)
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
58.3%Stage 2 (Cohort 1A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
—Stage 2 (Cohort 2A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
—
Most frequent reported AEs
a
anaemia 34.8%
neutropenia 31.5%
fatigue 29.5%
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 2 more results
anaemia 31.5%
fatigue 29.8%
diarrhoea 29.5%
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
nausea 58.3%
diarrhoea 50%
fatigue 41.7%
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
—

Notes

  1. aPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dostarlimab

Overall Survival 11.9 vs 11.3 Docetaxel months
time to event · months
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
11.8 vs 11.3 Docetaxel months
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
Overall Survival 11.9 months
time to event · months
No placebo or comparator arm
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
11.8 months
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
ORR 18.7% (n=305) vs 14.5% (n=152) Docetaxel
responder rate · % of participants
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
18.3% (n=301) vs 14.5% (n=152) Docetaxel
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
PFS 4.4 vs 4.1 Docetaxel months
time to event · months
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
4.2 vs 4.1 Docetaxel months
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
Duration of Response 8.3 vs 8.8 Docetaxel months
time to event · months
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
7.1 vs 8.8 Docetaxel months
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
ORR 9.1% (n=11)
responder rate · % of participants
No placebo or comparator arm
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
Duration of Response 21.5 months
time to event · months
No placebo or comparator arm
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
Disease Control 54.5% (n=11)
responder rate · % of participants
No placebo or comparator arm
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
PFS 4.4 months
time to event · months
No placebo or comparator arm
NCT03308942 · Phase 2 · registry result, not featured evidence · combination

Serplulimab

Intracranial PFS 13.1 months
absolute value · months
No placebo or comparator arm
NCT05807893 · Phase 2/3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dostarlimab's landscape · Serplulimab's landscape